Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
35 shown of 2,726 total abstracts
  1. Abstract 95732026-09-01 · 21:30 CT · S100A
    Quality of life outcomes with Tecentriq in patients with NSCLC
    A. Spira, C. Robert · Stanford Cancer Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  2. Abstract 94672026-09-02 · 13:00 CT · S100A
    Quality of life outcomes with Tagrisso in patients with NSCLC
    L. Paz-Ares, C. Robert, H. Borghaei · National Cancer Center Japan
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  3. Abstract 94562026-09-05 · 13:00 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-8
    C. Robert, S. Peters, A. Spira · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  4. Abstract 97402026-09-03 · 15:30 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-150
    S. Tolaney, H. Rugo, N. Rizvi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  5. Abstract 90802026-09-04 · 15:45 CT · S100A
    FLAURA-479: Tagrisso (osimertinib) 1L in NSCLC
    J. Cortes, H. Rugo, S. Modi, et al. · Mayo Clinic
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  6. Abstract 92532026-09-05 · 16:00 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-691 study)
    S. Antonia, N. Rizvi, G. Curigliano, et al. · Chinese University of Hong Kong
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  7. Abstract 92672026-09-04 · 21:30 CT · S406
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-704 study)
    M. Reck, N. Rizvi, A. Spira · University of Chicago
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  8. Abstract 99372026-09-04 · 18:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-515 study)
    G. Curigliano, S. Peters, C. Robert, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  9. Abstract 91082026-09-02 · 15:30 CT · S406
    FLAURA-747: Tagrisso (osimertinib) neoadjuvant in NSCLC
    M. Krop, C. Saura, R. Herbst, et al. · Institut Gustave Roussy
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  10. Abstract 92902026-09-04 · 19:45 CT · S100A
    Long-term follow-up of Imfinzi 2L for NSCLC: PACIFIC-426
    F. Andre, S. Peters, N. Rizvi, et al. · Cleveland Clinic
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  11. Abstract 99772026-09-05 · 14:45 CT · S100A
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    T. Mok, C. Robert, S. Peters, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  12. Abstract 93282026-09-04 · 16:30 CT · S406
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-592 study)
    J. Cortes, P. Schmid, R. Herbst, et al. · Royal Marsden Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  13. Abstract 94782026-09-03 · 19:00 CT · Arie Crown Theater
    Quality of life outcomes with Enhertu in patients with NSCLC
    M.C. Garassino, S. Antonia, N. Rizvi, et al. · Stanford Cancer Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  14. Abstract 97892026-09-04 · 21:00 CT · E450
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-526
    P. Schmid, H. Rugo, M.C. Garassino, et al. · Stanford Cancer Institute
    Education SessionLung Cancer—Small Cell📄🖼️
  15. Abstract 93292026-09-02 · 19:00 CT · S406
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    H. Rugo, T. Mok, R. Herbst, et al. · Massachusetts General Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  16. Abstract 94772026-09-03 · 16:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-796 study)
    L. Paz-Ares, C. Saura, R. Herbst, et al. · National Cancer Center Japan
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  17. Abstract 93402026-09-03 · 16:30 CT · Hall B1
    IMpower-16: Tecentriq (atezolizumab) 2L in NSCLC
    T. Mok, M.C. Garassino, A. Spira · Johns Hopkins Kimmel Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  18. Abstract 90762026-09-01 · 15:15 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-905 study)
    A. Spira, R. Herbst, H. Rugo · Peter MacCallum Cancer Centre
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  19. Abstract 97422026-09-02 · 14:30 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-475
    R. Herbst, S. Antonia, C. Saura, et al. · Royal Marsden Hospital
    Education SessionLung Cancer—Small Cell📄🖼️
  20. Abstract 97472026-09-01 · 16:15 CT · S100A
    FLAURA-901: Tagrisso (osimertinib) neoadjuvant in NSCLC
    L. Paz-Ares, G. Curigliano, H. Rugo, et al. · National Cancer Center Japan
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  21. Abstract 90352026-09-03 · 20:45 CT · S406
    Long-term follow-up of Enhertu 1L for NSCLC: DESTINY-Breast-107
    S. Modi, R. Herbst, J. Cortes, et al. · National Cancer Center Japan
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  22. Abstract 94312026-09-01 · 16:30 CT · E450
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    M. Reck, P. Schmid, J. Brahmer · Massachusetts General Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  23. Abstract 93432026-09-05 · 19:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-200 study)
    M.C. Garassino, H. Borghaei, L. Paz-Ares · Vall d'Hebron Institute of Oncology
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  24. Abstract 90332026-09-05 · 15:15 CT · S100A
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-169
    L. Paz-Ares, J. Brahmer · Mayo Clinic
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  25. Abstract 99522026-09-04 · 18:30 CT · S100A
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-371 study)
    S. Modi, C. Robert, M. Reck · Johns Hopkins Kimmel Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  26. Abstract 99742026-09-02 · 18:30 CT · S100A
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-680 study)
    T. Mok, G. Curigliano · Johns Hopkins Kimmel Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  27. Abstract 90732026-09-04 · 15:15 CT · S406
    Long-term follow-up of Imfinzi neoadjuvant for NSCLC: PACIFIC-329
    S. Modi, T. Mok, C. Saura · University of Chicago
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  28. Abstract 91032026-09-02 · 19:15 CT · Arie Crown Theater
    Quality of life outcomes with Opdivo in patients with NSCLC
    M. Krop, E. Winer, C. Robert, et al. · Chinese University of Hong Kong
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  29. Abstract 99262026-09-05 · 19:15 CT · S100A
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-542
    N. Rizvi, E. Winer, S. Peters, et al. · Royal Marsden Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  30. Abstract 94912026-09-03 · 18:30 CT · S406
    Long-term follow-up of Opdivo maintenance for NSCLC: CheckMate-662
    L. Paz-Ares, S. Peters · Memorial Sloan Kettering Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  31. Abstract 92112026-09-03 · 16:30 CT · S406
    Long-term follow-up of Imfinzi 2L for SCLC: PACIFIC-3
    F. Andre, M.C. Garassino · Mayo Clinic
    Education SessionLung Cancer—Small Cell📄🖼️
  32. Abstract 96672026-09-02 · 15:15 CT · S100A
    Long-term follow-up of Imfinzi 3L+ for NSCLC: PACIFIC-251
    M. Reck, H. Rugo, L. Paz-Ares, et al. · National Cancer Center Japan
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  33. Abstract 95792026-09-03 · 14:00 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-780 study)
    J. Brahmer, J. Cortes, G. Curigliano · Royal Marsden Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  34. Abstract 98562026-09-04 · 13:15 CT · S406
    CheckMate-416: Opdivo (nivolumab) 3L+ in NSCLC
    S. Antonia, J. Cortes · Vall d'Hebron Institute of Oncology
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  35. Abstract 93082026-09-04 · 20:00 CT · E450
    Quality of life outcomes with Keytruda in patients with NSCLC
    F. Andre, S. Peters, S. Modi · Memorial Sloan Kettering Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.